Skip to main content Click to view our accessibility statement

Videos

Chapter 2

Why ONGENTYS

Watch Dr. Hauser and Dr. Farmer discuss the efficacy and safety of ONGENTYS.

Hear from your peers about their experiences with ONGENTYS

Parkinson's Treatment Approach Video Thumbnail

Chapter 1

Parkinson’s Treatment Approach

Hear Dr. Hauser and Dr. Farmer discuss their approach to treating PD.

Why ONGENTYS Video Thumbnail

Chapter 2

Why ONGENTYS

Watch Dr. Hauser and Dr. Farmer discuss the efficacy and safety of ONGENTYS.

Clinical Experience With ONGENTYS Video Thumbnail

Chapter 3

Clinical Experience with ONGENTYS

Dr. Hauser and Dr. Farmer share insights about prescribing ONGENTYS.

Explore the science behind the COMT enzyme and ONGENTYS

Mechanism of Disease Video Thumbnail

MOD

See the impact of the COMT enzyme and how it can make levodopa’s path to the brain more difficult.

Mechanism of Action Video Thumbnail

MOA

Watch the science behind ONGENTYS and how it helps more levodopa reach the brain.

Looking for more tools and resources including samples?

Get Samples

VIEW FULL IMPORTANT SAFETY INFORMATION


Important Information

INDICATION & USAGE

ONGENTYS® (opicapone) capsules is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing "off" episodes.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

ONGENTYS is contraindicated in patients with:

  • Concomitant use of non-selective monoamine oxidase (MAO) inhibitors.
  • Pheochromocytoma, paraganglioma, or other catecholamine secreting neoplasms.

WARNINGS & PRECAUTIONS

Cardiovascular Effects with Concomitant Use of Drugs Metabolized by Catechol-O-Methyltransferase (COMT) - Possible arrhythmias, increased heart rate, and excessive changes in blood pressure may occur with concomitant use of ONGENTYS and drugs metabolized by COMT, regardless of the route of administration (including inhalation). Monitor patients treated concomitantly with ONGENTYS and drugs metabolized by COMT.

Falling Asleep During Activities of Daily Living and Somnolence - Patients have reported falling asleep while engaged in activities of daily living, including driving, which may result in accidents. Consider discontinuing ONGENTYS or adjusting other dopaminergic/sedating medications. Advise patients to avoid driving and other potentially dangerous activities.

Hypotension/Syncope - Monitor patients for hypotension and advise patients about the risk for syncope. If necessary, consider discontinuing ONGENTYS or adjusting the dosage of other medications that can lower blood pressure.

Dyskinesia - ONGENTYS may cause or exacerbate dyskinesia. Consider levodopa or dopaminergic medication dose reduction.

Hallucinations and Psychosis - Consider stopping ONGENTYS if these occur. Patients with a major psychotic disorder should ordinarily not be treated with ONGENTYS.

Impulse Control/Compulsive Disorders - Patients may experience intense urges (eg, gambling, sexual, spending money, binge eating) and the inability to control them. It is important for prescribers to ask about the development of new or increased urges. Monitor for occurrence of intense urges and consider discontinuing ONGENTYS if they occur.

Withdrawal-Emergent Hyperpyrexia and Confusion - A symptom complex resembling neuroleptic malignant syndrome can develop with rapid dose reduction or withdrawal of drugs that increase central dopaminergic tone. When discontinuing ONGENTYS, monitor patients and consider adjustment of dopaminergic therapies as needed.

ADVERSE REACTIONS

The most common adverse reactions (incidence at least 4% and greater than placebo) were dyskinesia, constipation, blood creatine kinase increased, hypotension/syncope, and weight decreased.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see ONGENTYS full Prescribing Information.